Differences between the European Union and United States of America in Drug Regulatory Affairs Affect Global Patient Safety Standards and Public Health Awareness: The Case of Deferasirox and Other Iron Chelating Drugs
Regulatory policies on drugs have a major impact on patient safety and survival. Some pharmaceutical companies employ all possible methods to achieve maximum sales in relation to the monopoly of their patented drugs, leading sometimes to irregularities and illegal activities. Misinformation on the o...
Main Author: | George J. Kontoghiorghes |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-07-01
|
Series: | Medicines |
Subjects: | |
Online Access: | https://www.mdpi.com/2305-6320/8/7/36 |
Similar Items
-
Comparison of iron chelation effects of deferoxamine, deferasirox, and combination of deferoxamine and deferiprone on liver and cardiac T2* MRI in thalassemia maior
by: Shahla Ansari, et al.
Published: (2017-06-01) -
Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes
by: Kontoghiorghe CN, et al.
Published: (2016-01-01) -
Iron Chelator Drugs in Transfusion Dependent Thalassemia: a Review
by: M Hashemieh
Published: (2020-08-01) -
Long-Term Effects of Iron Chelating Agents on Ocular Function in Patients with Thalassemia Major
by: Nuzzi R, et al.
Published: (2021-05-01) -
Reducing the iron burden and improving survival in transfusion-dependent thalassemia patients: current perspectives
by: Bayanzay K, et al.
Published: (2016-08-01)